Compare AGCO Corporation (AGCO) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AGCO Corporation vs Gilead Sciences, Inc. — how do they compare? AGCO Corporation trades at $101.69 (market cap $7.10B), while Gilead Sciences, Inc. trades at $136.73 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 23.7× AGCO Corporation's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| AGCO | GILD | |
|---|---|---|
Market Cap | $7.10B | $168.35B |
Sector | Industrials | Health |
52-Week High | $140.49 | $155.80 |
52-Week Low | $100.14 | $110.56 |
Enterprise Value | $9.37B | $191.42B |
Dividend Yield | 1.18% | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGCO Corporation (NYSE: AGCO) is trading at $100.87, down 1.91% on the day, following disappointing Q2 2026 earnings that missed expectations. The agricultural equipment manufacturer faces bearish technical signals with support at $99 and resistance at $103. Fundamentally, the company maintains reasonable valuation metrics (P/E 14.03, P/S 0.72) despite recent earnings volatility, with 2025 revenue of $10.08 billion and net income of $726.5 million. Recent leadership changes and multiple securities investigations have created investor uncertainty.
The outlook remains cautious as AGCO navigates weaker industry demand and lowered 2026 guidance. While analyst consensus suggests 23.5% upside to the $124.63 price target, near-term headwinds from agricultural market softness and legal scrutiny present significant risks. The stock's current valuation may offer value for patient investors, but execution risks and market sentiment require careful monitoring.
Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.
Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AGCO Corporation
Agco is a global manufacturer of agricultural equipment. The company has five principal brands: Fendt, Massey Ferguson, Challenger, Valtra, and GSI. Unlike its competitors, Agco's product line extends beyond self-propelled equipment and implements by offering grain handling systems and livestock management solutions. Its products are available through a global dealer network, which includes over 3,200 dealer and distribution locations. Additionally, Agco offers both retail and wholesale financing to customers through its joint venture with Rabobank, a European food and agriculture focused bank.
Read more on AGCO →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
